hotspot -WSS

hotspot

author：comprehensive 2025-09-30 00:09:30 - browse：9618

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

explore

WSS

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Sophia Smith scores twice for US in in 3

Reports of telehealth's death have been greatly exaggerated

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

hotspot

knowledge

Medical records are filled with copy

Digital health: a case of mistaken identity

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Novartis develops a rapidly manufactured CAR

New air purifier tech could be key to improving indoor air quality

Scrutiny of post

The cancer drug shortage isn’t new — and neither are the solutions

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

New air purifier tech could be key to improving indoor air quality

As a primary care physician, here's how I hope to partner with AI

focus

My chronic pain journey would have been easier knowing 5 things % STAT

PrEP can help anyone prevent HIV. Why do so few people take it?

How to protect coverage of PrEP

Eyeing GLP

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Biogen joins immunology wave with $1.15 billion acquisition of HI

explore

explore

explore

hotspot